3B Blackbio Dx Limited Q2 FY26 results deck summary

Results deck of 13 Nov 2025, summarised by AI from the filing.

H1 2025-26 consolidated revenue ₹5,613.67 lakh and PAT ₹2,768.21 lakh, with MDx India growth guided at 15%–20% for FY 2025–26.

Key takeaways

1. H1 results Consolidated revenue from operations ₹5,613.67 lakh (H1 2024-25: ₹4,858.10 lakh) and PAT ₹2,768.21 lakh (H1 2024-25: ₹2,616.04 lakh).
2. Change CORIS Bioconcept acquired on 29 August 2025, consolidated from that date with revenue of ₹362.70 lakh and EBITDA of ₹(6.93) lakh.
3. Driver Repeat business and new customer additions across a wide product range, with exports and TRUPCR Europe growth.
4. Risk Increasing competition puts pressure on margins, and geopolitical issues in the Middle East and Ukraine may affect sales.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
• Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
• Q2 FY26: Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (19 Aug 2025)
• Q4 FY25: Results deck (28 May 2025)
• Other events: Strategy deck (14 Aug 2025)